LB1106 An exploratory open label phase 1b study of secukinumab in patients with moderate to severe papulopustular rosacea

Background: Recent analyses of rosacea skin biopsies implicated IL-17A in rosacea pathogenesis. Current rosacea treatment options are limited and no cure exists. Objective: Assess the potential benefit of secukinumab in patients with moderate-to-severe papulopustular rosacea. Methods: After IRB approval and written informed consent, a total of 23 participants received secukinumab at 300 mg weekly for five weeks then monthly for two months. Papule count, erythema, global severity, and adverse events at 0 and 16 weeks were assessed by three board certified dermatologists blinded to pre- or post-treatment. Results: The primary endpoint of mean change in papule count after 16 weeks of treatment was reduction in 8.4 papules, standard deviation 11.0 (p=0.01). Significant changes at week 16 in secondary endpoints, were: mean decrease of 0.5 points on the five point Clinician’s Global Erythema Assessment (p=0.02), mean decrease of 0.4 points on the five point Clinician’s Global Severity Score (p=0.03), and mean decrease of 0.9 points on the five point Rosacea Quality of Life Scale (p